Hepatitis C virus and human immunodeficiency virus: a dangerous dealing

Area of Science:

• Hepatology and Infectious Diseases
• Clinical Medicine

Background:

• Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is prevalent, particularly among intravenous drug users, hemophiliacs, and men who have sex with men.
• HIV accelerates HCV progression, while antiretroviral therapy can mitigate liver disease mortality through immune restoration.

Purpose of the Study:

• To review the current clinical landscape of HIV/HCV coinfection.
• To emphasize the importance of screening for HCV in all individuals with HIV.
• To discuss diagnostic approaches and treatment modalities for coinfected patients.

Main Methods:

• Review of existing literature and clinical guidelines concerning HIV/HCV coinfection.
• Analysis of diagnostic methods, including antibody testing and quantitative HCV-RNA levels.
• Evaluation of treatment recommendations, such as interferon-based therapies and liver transplantation.

Main Results:

• Quantitative HCV-RNA testing is essential for diagnosis confirmation in at-risk populations.
• Treatment strategies prioritize managing HIV due to its faster progression.
• Current recommendations involve pegylated interferon and ribavirin, with duration dependent on HCV genotype.

Conclusions:

• HIV/HCV coinfection necessitates integrated management approaches.
• Screening for HCV in HIV-positive individuals is vital.
• Liver transplantation outcomes in coinfected patients are comparable to HIV-negative controls.